A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

Leapman, MD, MHS, associate professor of urology at Yale University, addresses a critical and often overlooked limitation in the current landscape of prostate cancer biomarkers: while these tools have ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

A set of genes may identify a prostate cancer subtype in African American patients that needs aggressive treatment. Specific genes may signal aggressive prostate cancer (PCa) in African American men, ...

Urine panel had AUC of 0.96 and 0.92 with development and validation datasets, respectively, compared with 0.83 and 0.76 for urinary PCA3 RNA. HealthDay News — A urine-based biomarker panel has high ...

Dr Petros Grivas surveys several exciting developments in prostate cancer research, including AI-driven biomarker analysis from the STAMPEDE trial, to identify high-risk patients who may benefit from ...

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...

Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the longest-running European trial show one life saved for every six men diagnosed, a ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...